Doris Helbig

1.0k total citations
79 papers, 656 citations indexed

About

Doris Helbig is a scholar working on Dermatology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Doris Helbig has authored 79 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Dermatology, 30 papers in Oncology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Doris Helbig's work include Sarcoma Diagnosis and Treatment (17 papers), Vascular Tumors and Angiosarcomas (15 papers) and Cutaneous lymphoproliferative disorders research (13 papers). Doris Helbig is often cited by papers focused on Sarcoma Diagnosis and Treatment (17 papers), Vascular Tumors and Angiosarcomas (15 papers) and Cutaneous lymphoproliferative disorders research (13 papers). Doris Helbig collaborates with scholars based in Germany, United States and Austria. Doris Helbig's co-authors include Uwe Paasch, Cornelia Mauch, Alexander Quaas, Reinhard Büttner, Jan C. Simon, Jan C. Simon, Sebastian Klein, Michaela A. Ihle, Reinhard Buettner and Michael Kendler and has published in prestigious journals such as Scientific Reports, American Journal of Public Health and Clinical Cancer Research.

In The Last Decade

Doris Helbig

73 papers receiving 638 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Doris Helbig Germany 16 302 224 218 104 104 79 656
Teresa Russo Italy 15 294 1.0× 175 0.8× 82 0.4× 92 0.9× 214 2.1× 67 642
Michael D. Ioffreda United States 11 179 0.6× 104 0.5× 85 0.4× 64 0.6× 101 1.0× 40 492
B. Cooke Australia 12 196 0.6× 249 1.1× 57 0.3× 76 0.7× 216 2.1× 19 680
B Chouvet France 15 237 0.8× 165 0.7× 100 0.5× 213 2.0× 163 1.6× 64 646
A.M. Cesinaro Italy 13 177 0.6× 362 1.6× 121 0.6× 45 0.4× 243 2.3× 21 586
M. Walsh United Kingdom 15 150 0.5× 81 0.4× 88 0.4× 108 1.0× 245 2.4× 42 700
Birgit Kahle Germany 15 191 0.6× 123 0.5× 121 0.6× 55 0.5× 92 0.9× 81 832
M. Dandurand France 14 190 0.6× 207 0.9× 45 0.2× 85 0.8× 173 1.7× 48 664
Petra Gottlöber Germany 14 165 0.5× 131 0.6× 75 0.3× 31 0.3× 173 1.7× 29 518
Adrienne Rencic United States 12 68 0.2× 170 0.8× 107 0.5× 142 1.4× 68 0.7× 23 552

Countries citing papers authored by Doris Helbig

Since Specialization
Citations

This map shows the geographic impact of Doris Helbig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doris Helbig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doris Helbig more than expected).

Fields of papers citing papers by Doris Helbig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doris Helbig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doris Helbig. The network helps show where Doris Helbig may publish in the future.

Co-authorship network of co-authors of Doris Helbig

This figure shows the co-authorship network connecting the top 25 collaborators of Doris Helbig. A scholar is included among the top collaborators of Doris Helbig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doris Helbig. Doris Helbig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Noh, Ka‐Won, et al.. (2025). Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma. Clinical Cancer Research. 31(22). 4730–4744.
2.
Helbig, Doris, Corinna Bürger, Anne Fröhlich, et al.. (2025). Explainable, federated deep learning model predicts disease progression risk of cutaneous squamous cell carcinoma. npj Precision Oncology. 9(1). 205–205. 2 indexed citations
3.
Utikal, Jochen, Verena Müller, Jürgen C. Becker, et al.. (2024). S1‐Guideline Sebaceous Carcinoma. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 22(5). 730–747. 3 indexed citations
4.
Klein, Sebastian, Yuri Tolkach, Hans Christian Reinhardt, et al.. (2024). Proteomic analysis of pleomorphic dermal sarcoma reveals a fibroblastic cell of origin and distinct immune evasion mechanisms. Scientific Reports. 14(1). 12516–12516.
5.
Helbig, Doris, Edgar Dippel, Michael Erdmann, et al.. (2023). S1‐guideline cutaneous and subcutaneous leiomyosarcoma. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 21(5). 555–563. 3 indexed citations
6.
Helbig, Doris, Edgar Dippel, Michael Erdmann, et al.. (2023). S1‐Leitlinie dermales und subkutanes Leiomyosarkom. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 21(5). 555–564. 1 indexed citations
7.
Stebut, Esther von & Doris Helbig. (2023). Anatomische und funktionelle Unterschiede der Haut verschiedener Ethnien. Die Dermatologie. 74(2). 80–83. 3 indexed citations
8.
Toberer, Ferdinand, Holger A. Haenssle, Monika Heinzel‐Gutenbrunner, et al.. (2022). Metabolic Signature of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: Expression of Hypoxia-inducible Factor-1α and Several of Its Downstream Targets.. PubMed. 30(1). 25–31. 1 indexed citations
9.
Helbig, Doris & Sebastian Klein. (2022). Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas. Frontiers in Oncology. 12. 975342–975342. 6 indexed citations
10.
Schwab, M., et al.. (2021). Podoplanin is required for tumor cell invasion in cutaneous squamous cell carcinoma. Experimental Dermatology. 30(11). 1619–1630. 6 indexed citations
11.
Klein, Sebastian, Alexander Quaas, Ka‐Won Noh, et al.. (2020). Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy. Clinical Cancer Research. 26(21). 5638–5645. 21 indexed citations
12.
Klein, Sebastian, Cornelia Mauch, Svenja Wagener‐Ryczek, et al.. (2019). Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy. Cancer Immunology Immunotherapy. 68(6). 973–982. 20 indexed citations
13.
Wirtz, Markus & Doris Helbig. (2014). Granulomatöse Mycosis fungoides. Der Hautarzt. 65(4). 274–276. 1 indexed citations
14.
Braun, Stephan Alexander, Doris Helbig, Josef Frank, & S. Hanneken. (2012). Eruptive melanozytäre Nävi unter Behandlung einer Myasthenia gravis mit Azathioprin. Der Hautarzt. 63(10). 756–759. 3 indexed citations
15.
Braun, Stephan Alexander, S. Hanneken, J. Reifenberger, Doris Helbig, & Josef Frank. (2012). Hereditäre kutane Leiomyomatose. Der Hautarzt. 63(4). 276–278. 2 indexed citations
16.
Helbig, Doris, et al.. (2010). Nonablative skin rejuvenation devices and the role of heat shock protein 70: results of a human skin explant model. Journal of Biomedical Optics. 15(3). 38002–38002. 28 indexed citations
17.
Helbig, Doris, et al.. (2009). Elastolyse der mittleren Dermis. Der Hautarzt. 61(9). 779–784. 2 indexed citations
18.
Helbig, Doris, Marc Oliver Bodendorf, Sonja Grunewald, et al.. (2009). Immunohistochemical investigation of wound healing in response to fractional photothermolysis. Journal of Biomedical Optics. 14(6). 64044–64044. 56 indexed citations
19.
Helbig, Doris, Uwe Hillen, Stephan Grabbe, & Joachim Dissemond. (2007). Haut- und Schleimhautulzerationen bei heparininduzierter Thrombozytopenie (HIT) II. Der Hautarzt. 58(9). 774–780. 2 indexed citations
20.
Helbig, Doris, et al.. (1972). The care component score--a new system for evaluating quality of inpatient care.. American Journal of Public Health. 62(4). 540–546. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Teresa Russo Breakdown of academic impact, for papers by Michael D. Ioffreda Breakdown of academic impact, for papers by B. Cooke Breakdown of academic impact, for papers by B Chouvet Breakdown of academic impact, for papers by A.M. Cesinaro Breakdown of academic impact, for papers by M. Walsh Breakdown of academic impact, for papers by Birgit Kahle Breakdown of academic impact, for papers by M. Dandurand Breakdown of academic impact, for papers by Petra Gottlöber Breakdown of academic impact, for papers by Adrienne Rencic
Rankless by CCL
2026